High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ‐secretase inhibitor, RO4929097

Interest continues to build around the early application of patient selection markers to prospectively identify patients likely to show clinical benefit from cancer therapies. Hypothesis generation and clinical strategies often begin at the preclinical stage where responder and nonresponder tumor ce...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Oncol
Main Authors: He, Wei, Luistro, Leopoldo, Carvajal, Daisy, Smith, Melissa, Nevins, Tom, Yin, Xuefeng, Cai, James, Higgins, Brian, Kolinsky, Kenneth, Rizzo, Christine, Packman, Kathryn, Heimbrook, David, Boylan, John F.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2011
Assuntos:
Papers
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528291/
https://ncbi.nlm.nih.gov/pubmed/21315665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2011.01.001
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados